52,700 Shares in Ohr Pharmaceutical Inc. (OHRP) Acquired by GSA Capital Partners LLP
GSA Capital Partners LLP acquired a new position in shares of Ohr Pharmaceutical Inc. (NASDAQ:OHRP) during the second quarter, Holdings Channel reports. The firm acquired 52,700 shares of the company’s stock, valued at approximately $144,000. GSA Capital Partners LLP owned approximately 0.17% of Ohr Pharmaceutical at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in OHRP. Opaleye Management Inc. purchased a new stake in shares of Ohr Pharmaceutical during the first quarter worth about $1,175,000. Geode Capital Management LLC raised its stake in shares of Ohr Pharmaceutical by 3.9% in the first quarter. Geode Capital Management LLC now owns 152,915 shares of the company’s stock worth $490,000 after buying an additional 5,794 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Ohr Pharmaceutical by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 60,069 shares of the company’s stock worth $164,000 after buying an additional 757 shares in the last quarter. 11.32% of the stock is owned by hedge funds and other institutional investors.
Shares of Ohr Pharmaceutical Inc. (NASDAQ:OHRP) traded up 0.7004% during mid-day trading on Wednesday, hitting $2.7894. 45,984 shares of the stock traded hands. Ohr Pharmaceutical Inc. has a one year low of $2.44 and a one year high of $6.56. The company’s market cap is $89.55 million. The stock has a 50 day moving average price of $2.73 and a 200-day moving average price of $2.93.
Ohr Pharmaceutical (NASDAQ:OHRP) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, analysts forecast that Ohr Pharmaceutical Inc. will post ($0.94) earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on OHRP shares. Zacks Investment Research lowered shares of Ohr Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, July 30th. Brean Capital lowered shares of Ohr Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th. Finally, Roth Capital reaffirmed a “buy” rating and set a $13.00 target price on shares of Ohr Pharmaceutical in a research note on Thursday, June 16th.
Want to see what other hedge funds are holding OHRP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ohr Pharmaceutical Inc. (NASDAQ:OHRP).
Receive News & Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.